Acuitas Therapeutics Acquires Majority Stake in RNA Technologies & Therapeutics to Advance RNA-LNP Therapeutics
核心洞察
Acuitas Therapeutics (搜索), the global leader in lipid nanoparticle delivery systems, has acquired a majority stake in RNA Technologies & Therapeutics (搜索) to expand RNA-LNP therapeutic capabilities.
The strategic investment will provide partners streamlined access to complementary RNA optimization and LNP delivery expertise, reducing development complexity and accelerating clinical timelines.
RNA T&T will expand its operations and enhance its proprietary algorithmic platform for RNA sequence optimization while maintaining capabilities for personalized and n-of-few therapies.
Acuitas Therapeutics (搜索), the global leader in lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, has acquired a majority stake in RNA Technologies & Therapeutics (搜索) (RNA T&T), a Montreal-based company specializing in the design, optimization and manufacture of high-quality RNA constructs. The strategic investment aims to provide partners with integrated access to world-class RNA optimization and LNP delivery expertise.
Strategic Integration of RNA and LNP Technologies
The acquisition addresses a critical need in RNA therapeutic development, where optimization of both the mRNA payload and the LNP carrier is essential to maximize efficacy and safety. According to the companies, an integrated approach for these two key components derisks clinical programs and supports accelerated availability to patients in need.
While both companies will continue to operate independently, the investment will give partners of each company streamlined access to complementary expertise. By integrating these capabilities, partners can take a more holistic approach to RNA-LNP therapeutics, helping to reduce development complexity, accelerate clinical timelines and preemptively mitigate risk across multiple programs.
"As genetic medicines expand into more complex areas such as personalized therapies, biotechnology and pharmaceutical companies are seeking efficient access to RNA and LNP design and engineering expertise," said Dr. Thomas Madden, CEO of Acuitas Therapeutics (搜索). "Having worked extensively with RNA T&T over the last number of years, we are impressed with their scientific approach and technical know-how, which brings a level of precision and consistency that is critical in RNA drug development."
Expanding Capabilities for Personalized Medicine
The investment will enable RNA T&T to grow its operational footprint, further develop its proprietary algorithmic platform for RNA sequence optimization and expand its capabilities in small-batch GMP-grade production of personalized and n-of-few therapies.
"Acuitas is the ideal partner for our next phase of growth, as both companies are deeply rooted in science and equally committed to advance the next generation of RNA-LNP medicines," said Pierrino Torbey, Board Member and interim CEO of RNA T&T. "This investment deepens the relationship between Acuitas and RNA T&T, while also allowing the latter to grow its operational footprint."
The collaboration has already demonstrated significant clinical impact. RNA T&T co-founder and Scientific Advisor Mohamad-Gabriel Alameh, Ph.D., provided the RNA design for the first personalized CRISPR therapy administered to baby KJ Muldoon, highlighting the companies' capabilities in highly complex and personalized RNA programs.
Proven Track Record in RNA Therapeutics
Acuitas' clinically validated LNP technology has achieved profound global impact, most notably enabling the Pfizer-BioNTech (搜索) COVID-19 (搜索) vaccine, COMIRNATY®, which has protected billions of people in more than 180 countries. The technology also enables ONPATTRO® by Alnylam Pharmaceuticals (搜索), the first FDA-approved RNAi therapeutic for treating the rare and fatal disease transthyretin amyloidosis (搜索).
More recently, Acuitas' LNP technology has delivered other groundbreaking firsts, including the first in-human proof of concept for genome base editing and the first personalized CRISPR therapy.
Future Applications and Development
Today, Acuitas is advancing next-generation LNP to support a variety of therapeutic modalities. This includes targeted LNP for extrahepatic and in vivo CAR T-cell therapies, epigenetic medicines to modulate gene expression without altering DNA, and multivalent vaccines for infectious diseases such as malaria (搜索), HIV/AIDS (搜索), and tuberculosis (搜索), as well as oncology vaccines, including personalized cancer vaccines.
RNA T&T, founded in 2022 by leading RNA scientists and vaccinologists including Nobel Prize laureate Dr. Drew Weissman, specializes in collaborative design, optimization, and manufacture of RNA constructs. The company works closely with partners to refine sequences and deliver payload with superior biological performance, focusing on advancing the next generation of RNA therapeutics through rigorous science and innovative technologies.